GIP and obesity due to melanocortin 4 receptor deficiency: Non-pharmacological approaches, such as diet and exercise, are first-line management strategies for obesity, but novel drugs like glucagon-like peptide (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonists show promising results for weight loss [2].